The Global CancerBiomarkers Market, by Biomarker Type (Protein Biomarkers, GeneticBiomarkers, and Others), By Cancer Type (Breast Cancer, Lung Cancer, ProstateCancer, Kidney Cancer, Liver Cancer, and Others), by End User (Hospitals,Academic and Cancer Research Institutes, Ambulatory Surgical Centers, andDiagnostic Laboratories), was valued US$ 33.7 billion in 2017 and is projectedto exhibit a CAGR of 14.2% over the forecast period (2017–2025).
Growing prevalence and incidenceof various types of cancer coupled with increasing need for early diagnosis ofcancers are the major factors driving growth of global cancer biomarkers marketover the forecast period. Continuous research and development and technologyadvancements in cancer biomarkers had led to introduction of better andaffordable biomarkers in the field of clinical diagnosis. For instance,according to the data published in Cell Metabolism Journal, in March 2018, ateam of Australian researchers found a unique metabolic marker, which can detectadenocarcinomas, a form of lung cancer. These metabolic biomarkers respond toimmunotherapies and offers simple, non-invasive blood test for early detectionof lung cancer.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/175
Browse 35 Market Data Tables and33 Figures spread through 160 Pages and in-depth TOC on "Cancer BiomarkersMarket, by Biomarker Type (Protein Biomarkers, Genetic Biomarkers and OtherCancer Biomarkers), By Cancer Type (Breast Cancer, Lung Cancer, ProstateCancer, Kidney Cancer, Liver Cancer and Other Cancers), by End User (Hospitals,Academic and Cancer Research Institutes, Ambulatory Surgical Centers,Diagnostic Laboratories) - Global Forecast to 2025"
In February 2018, researchers atGeorgetown-Lombardi Comprehensive Cancer Center, identified biomarkers, whichcan use liquid biopsies to predict response to cancer treatment and help inidentifying increasingly specific subsets of GI cancers to make treatmentdecisions. According to the data published in the European Journal of BreastHealth, in October 2017, body fluid tests can be used for early detection ofnew or recurrent breast cancer. This new approach includes tissue testing andbody fluid analysis of individuals diagnosed with breast cancer, for moreeffective cancer treatment. Moreover, manufacturers are focusing on developingnew cancer biomarkers, which would aid in early diagnosis of cancers and areused for oncology research studies. For instance, in November 2016, OxfordCancer Biomarkers Ltd. introduced ColoTox test for predicting risk of toxicitywith cancer chemotherapy tests. In December 2015, Olink Bioscience introducedProseek Multiplex Oncology II96x96: 92 human protein biomarker panel foroncology research.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/cancer-biomarkers-market-175
Key takeaways of the cancerbiomarkers market:
The global cancer biomarkersmarket is expected to expand at a CAGR of 14.2% during the forecast period(2017–2025), owing to increasing prevalence and incidence of cancer and growingdemand for early diagnosis of cancer. For instance, according to the CancerAtlas: 2017, there were an estimated 14.1 million new cancer cases in 2012.Moreover, India, China and other East and Central Asian countries accounted fornearly half of world’s new cancer cases and deaths, in 2017. In addition,according to the same source, by 2025, there will be an estimated 19.3 millionnew cancer cases and 11.4 million cancer deaths, in less developed regions.
Protein biomarkers segment holdsa major share in the market, owing to its extensive use in analyzing proteinconcentration in blood, tissue, urine, and other body fluids for early cancerdetection.
Liver cancer segment holdslargest revenue share in the market, owing to increasing number of liver cancerbiomarkers in the market and their ability for efficient diagnosis of earlyliver cancer
Among end users, diagnosticlaboratories segment holds the largest market share, owing to its ability toprovide advanced laboratory testing and research services for cancer researchto researchers and oncologist.
Some of the major playersinvolved in global cancer biomarkers market include BioMerieux S.A., Bard1 LifeSciences Limited, Bio-Rad Laboratories, Abbott Laboratories, Becton, Dickinsonand Company, Merck & Co., Inc., Qiagen N.V., and Thermo Fisher ScientificInc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/175
AboutCoherent Market Insights:
Coherent MarketInsights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
